The thread title clearly and misleadingly infers that marketing approval for Viraleze has been given whereas in reality land, the TGA is yet to make a decision which is up to 8 weeks away.
And then the chief pumper chimes in with: ’Targeting baby boomers on cruise ships would be an ideal cohort for Viraleze’
Sorry to break it to you captain, but the world’s largest baby boomer consumer market for cruise ships is Europe. Viraleze has been approved and marketed in this market since 2021 with peanuts to show for it.
Starpharma have missed this boat. And to add an extra sting in the face, long suffering shareholders have paid for it. $2.50 to 8.6 cents is quite the voyage.
